Allogene Therapeutics Inc
NASDAQ:ALLO
Allogene Therapeutics Inc
NASDAQ:ALLO
Price:
1.8
USD
11.11%
Market Cap:
$404.5m
Balance Sheet
Balance Sheet Decomposition
Allogene Therapeutics Inc
Allogene Therapeutics Inc
Balance Sheet Decomposition is not available for
Allogene Therapeutics Inc
Allogene Therapeutics Inc
Balance Sheet
Allogene Therapeutics Inc
Allogene Therapeutics Inc
Currency: USD
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
0
|
92
|
175
|
183
|
173
|
62
|
83
|
75
|
|
| Cash Equivalents |
0
|
92
|
175
|
183
|
173
|
62
|
83
|
75
|
|
| Short-Term Investments |
0
|
367
|
355
|
645
|
284
|
455
|
366
|
217
|
|
| Total Receivables |
0
|
0
|
2
|
3
|
2
|
2
|
2
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
3
|
2
|
2
|
2
|
2
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
9
|
12
|
14
|
12
|
10
|
9
|
9
|
|
| Total Current Assets |
0
|
468
|
545
|
845
|
471
|
529
|
459
|
303
|
|
| PP&E Net |
0
|
42
|
101
|
160
|
181
|
196
|
163
|
131
|
|
| PP&E Gross |
0
|
42
|
101
|
160
|
181
|
196
|
163
|
131
|
|
| Accumulated Depreciation |
0
|
1
|
6
|
13
|
23
|
37
|
51
|
63
|
|
| Intangible Assets |
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
262
|
63
|
208
|
370
|
72
|
4
|
81
|
|
| Other Long-Term Assets |
0
|
2
|
9
|
15
|
16
|
20
|
17
|
33
|
|
| Total Assets |
0
N/A
|
774
N/A
|
718
-7%
|
1 228
+71%
|
1 039
-15%
|
817
-21%
|
643
-21%
|
549
-15%
|
|
| Liabilities | |||||||||
| Accounts Payable |
0
|
12
|
9
|
10
|
10
|
14
|
6
|
5
|
|
| Accrued Liabilities |
0
|
17
|
24
|
45
|
38
|
40
|
31
|
30
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
39
|
0
|
1
|
0
|
0
|
|
| Total Current Liabilities |
0
|
30
|
33
|
94
|
48
|
55
|
37
|
36
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
41
|
56
|
54
|
74
|
97
|
94
|
91
|
|
| Total Liabilities |
0
N/A
|
71
N/A
|
89
+26%
|
148
+67%
|
122
-18%
|
151
+24%
|
131
-14%
|
127
-3%
|
|
| Equity | |||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
212
|
396
|
646
|
903
|
1 236
|
1 562
|
1 820
|
|
| Additional Paid In Capital |
0
|
914
|
1 024
|
1 726
|
1 822
|
1 912
|
2 075
|
2 242
|
|
| Other Equity |
0
|
0
|
1
|
0
|
3
|
10
|
1
|
0
|
|
| Total Equity |
0
N/A
|
703
N/A
|
629
-11%
|
1 080
+72%
|
916
-15%
|
666
-27%
|
512
-23%
|
422
-18%
|
|
| Total Liabilities & Equity |
0
N/A
|
774
N/A
|
718
-7%
|
1 228
+71%
|
1 039
-15%
|
817
-21%
|
643
-21%
|
549
-15%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
115
|
122
|
124
|
141
|
143
|
144
|
169
|
212
|
|
Switch to:
Switch to:
See Also
Discover More
